Imagine a mental reset button for people facing the end of their lives with severe anxiety or depression. This project uses a controlled dose of a psychedelic compound to help patients find peace when standard medicines fail. It's like providing a guided emotional journey to ease the heaviest burdens of terminal illness.
Palliative care patients with COPD, ALS, and MS suffer from severe psychological distress that current drugs cannot treat. This creates a gap in care that reduces quality of life for patients and families.
A standardized therapy manual, a digital care platform, and a GMP-certified drug delivery system for psilocybin.
If you are a drug manufacturer dealing with the lack of effective treatments for end-of-life anxiety — this project developed a standardized therapy manual and GMP-certified drug delivery process that ensures patient safety and consistent results.
If you are a tech provider dealing with fragmented post-treatment care — this project developed a digital care platform and peer-support networks that maintain patient wellbeing after the clinical session.
If you are a clinic owner dealing with high patient distress in COPD or ALS cases — this project developed a trained therapist model and clinical protocol that can be integrated into care services to improve quality of life.
Based on available project data, specific pricing is not mentioned, but the project aims to create a cost-effective deployment model for European healthcare systems.
The project uses a multi-centre trial across 4 countries and GMP-certified drug manufacturing, suggesting a scalable clinical model.
Based on available project data, specific patents are not listed, but the project has produced a standardized therapy manual and a digital care platform.
The project has secured full regulatory and ethical approval in the Netherlands, Denmark, Portugal, and the Czech Republic.
The project runs from 2024-01-01 to 2027-12-31, with the first 18 months focused on establishing the operational foundation.
The consortium is heavily weighted toward clinical and academic expertise, featuring 20 partners across 8 countries. With 6 universities and 3 research centers, the focus is scientific validation, though the inclusion of 3 SMEs and a 15% industry ratio indicates a clear path toward commercial translation and practical application in healthcare settings.
Contact Academisch Ziekenhuis Groningen in the Netherlands
Contact us to explore licensing the therapy manual or digital platform.
